Health ConditionsSIBO is defined as a bacterial population in the small intestine exceeding 105–106 organisms/mL. Normally, fewer than 103 organisms/mL are found in the upper small intestine, and the majority of these are Gram-positive organisms. The term is generally applied to a clinical disorder where symptoms, clinical signs, and/or laboratory abnormalities are attributed to changes in the numbers of bacteria or in the composition of the bacterial population in the small intestine.
The medical phenomenon currently known as SIBO was identified several decades ago by Faber, who described it in 1897 in the form of a case report of "blind-loop syndrome." Currently, SIBO is defined as a form of dysbiosis characterized by increased numbers of bacteria colonizing the small intestine, possibly with some characteristics of the colon microbiota.
The concept of SIBO arose in the context of maldigestion and malabsorption among patients with obvious risk factors that permitted the small bowel to be colonized by potentially injurious colonic microbiota. Such colonization resulted in clinical signs, symptoms, and laboratory abnormalities that were explicable within a coherent pathophysiological framework.
Thanks to ready access to hydrogen breath testing, SIBO is now commonly diagnosed among individuals presenting with a variety of gastrointestinal and even non-gastrointestinal symptoms. Its definition, however, remains controversial and true prevalence, accordingly, undefined.
Patients with SIBO vary in presentation, from being only mildly symptomatic to suffering from chronic diarrhea, weight loss, and malabsorption. Symptoms traditionally linked to SIBO include bloating, diarrhea, and abdominal pain/discomfort. Steatorrhea may be seen in more severe cases.
These excess organisms result in multiple intestinal symptoms like abdominal pain, bloating, diarrhea, and rarely malabsorption. The clinical picture can extend beyond the gut: this excessive bacterial biomass disrupts host physiology in a myriad of ways, leading to gastrointestinal and non-gastrointestinal symptoms and complications. SIBO is a common cause of non-specific gastrointestinal symptoms such as chronic abdominal pain, abdominal distention, diarrhoea, and flatulence, amongst others.
The presence of SIBO is detected in 33.8% of patients with gastroenterological complaints who underwent testing. Recently, an increase in the number of diagnosed SIBO cases has been observed, which is primarily due to the availability of noninvasive breath tests that facilitate the diagnostic process.
When the protective mechanisms — peristalsis, stomach acid — against excessive bacterial growth fail, small intestinal bacterial overgrowth (SIBO) can manifest. The antimicrobial effects were created by gastric acid, bile, or pancreatic enzymes; adequate gut motility; normal intestinal anatomy; and the patency of the ileocecal valve to maintain homeostasis.
The migrating motor complex (MMC) is a cyclic, recurring motility pattern that occurs in the stomach and small bowel during fasting; it is interrupted by feeding. The MMC is present in the gastrointestinal tract of many species, including humans. The complex can be subdivided into four phases, of which phase III is the most active, with a burst of contractions originating from the antrum or duodenum and migrating distally.
These motor complexes trigger peristaltic waves, which facilitate transportation of indigestible substances such as bone, fiber, and foreign bodies from the stomach, through the small intestine, past the ileocecal sphincter, and into the colon. The physiological role of the MMC is incompletely understood, but its absence has been associated with gastroparesis, intestinal pseudo-obstruction, and small intestinal bacterial overgrowth.
Patients with SIBO and IBS have on average a third as many MMC phase III events, with those events being roughly 30% shorter on average. Eradication of bacterial overgrowth has been shown to partially restore MMC activity.
Fat malabsorption occurs as a result of bacterial deconjugation of bile salts. In addition, free bile acids are toxic to the intestinal mucosa, resulting in mucosal inflammation and malabsorption. Deconjugated bile salts are reabsorbed in the jejunum rather than the ileum, leading to impaired micelle formation, fat malabsorption, and deficiencies in fat-soluble vitamins (A, D, E, and K).
Carbohydrate malabsorption develops as a result of premature breakdown of sugars by bacteria in conjunction with decreased disaccharidase activity secondary to disruption of the intestinal brush border. Protein malabsorption can occur because of digestion by bacteria, whereas protein-losing enteropathies can develop as a result of mucosal damage.
The increased microbial density in the small intestine is thought to result in fat malabsorption (including fat-soluble vitamins) and increased intestinal secretion due to early deconjugation of bile acids by bacteria, accelerated transit driven by metabolic products from excessive microbial fermentation of carbohydrates, and anemia due to increased vitamin B12 utilization by bacteria.
Some typical laboratory findings of SIBO are elevated folate and, less commonly, vitamin B12 deficiency, especially if intake is low and/or if stores are borderline. Folate levels, however, are usually normal or elevated in the context of SIBO because bacteria are able to synthesize folate. Through the complication of steatorrhea associated with fat maldigestion and malabsorption, SIBO is complicated by malabsorption of fat-soluble vitamins. Vitamin A, D, and E deficiencies can all be seen in SIBO. Because vitamin K is synthesized by luminal bacteria, deficiency of this vitamin is rarely seen in the context of SIBO.
Specifically, fat maldigestion and malabsorption can lead to deficiencies in fat-soluble vitamins A, D, and E. Other vitamin and mineral deficiencies can result from SIBO, including vitamin B12, thiamine, nicotinamide, and iron.
Cobalamin (vitamin B12) deficiency appears to occur commonly in SIBO patients as a result of increased vitamin B12 use by excess anaerobic bacteria, and the absorption of vitamin B12 is also significantly reduced in SIBO patients due to the competitive uptake by luminal bacteria. Vitamin B12 deficiency is known to potentially lead to an increase in homocysteine levels, and elevated plasma homocysteine is an important risk factor for cardiovascular disease.
Motility disorders are likely the main contributor to SIBO in older adults and in the general population. The slowdown of intestinal transit may be due to motor dysfunction of the intestine in diseases of the gut, autonomic diabetic polyneuropathy, and portal hypertension, or a decrease in the motor-stimulating influence of thyroid hormones.
In systemic sclerosis (SSc), intestinal hypomotility caused by the vasculopathy, smooth muscle atrophy, and subsequent fibrosis leading to small bowel stasis causes bacterial colonization and ultimately leads to SIBO.
Stasis and recirculation of intestinal contents due to fistulas, enterostomies, and anastomoses also predispose to SIBO, explaining its association with Crohn's disease, radiation enteropathy, and reconstructive gastrointestinal surgery.
Proton pump inhibitor (PPI) use is also considered an independent risk factor, observed in up to 50% of subjects with unexplained gastrointestinal symptoms. The prevalence of SIBO in patients with intestinal failure using PPI/acid-suppressing agents (72.0%, 95% CI 57.5–83.8) was numerically higher compared with patients with intestinal failure not using these agents (47.6%, 95% CI 25.7–70.2).
Chronic pancreatitis is another multifactorial cause, through reduced intestinal motility due to both the inflammatory process and narcotic use, as well as intestinal obstruction.
Twenty-nine percent of diabetic patients tested positive for SIBO, and the risk of SIBO in diabetic patients was 2.91 times higher than that in patients without diabetes. Diabetes could be a predisposing factor for the development of SIBO, especially among patients diagnosed by jejunal aspirate culture or those in Western populations.
In one large retrospective series based on duodenal aspirates obtained from patients under investigation for a variety of problems, the main risk factors for SIBO were older age, steatorrhea, and the use of narcotics; significantly associated disorders were inflammatory bowel disease, chronic pancreatitis, and jejunal disorders.
The luminal competition with the host for nutrients in SIBO may further contribute to malnutrition. Furthermore, the risks of bloating (OR = 3.02, p = 0.02) and flatulence (OR = 4.70, p = 0.01) were increased in SIBO-positive IBD patients.
Altered bowel motility, visceral hypersensitivity, abnormal brain-gut interactions, autonomic dysfunction, low-grade mucosal inflammation, and activation of mucosal immunity are risk factors for SIBO that can cause various symptoms of IBS.
The suggestion that SIBO may be a causative factor in irritable bowel syndrome and of its constituent symptoms has sparked debate and controversy on the very definition of SIBO. In a number of diseases, including cirrhosis, metabolic-associated fatty liver disease (MAFLD), diabetes, and pancreatitis, an association was found between disease severity and the presence of SIBO.
Berberine is a natural pentacyclic isoquinoline alkaloid extracted from many popular medicinal plants such as the genera Berberis, Coptis, and Hydrastis. Plants in these genera have been used in Ayurvedic, Chinese, and Native American traditional medicine for centuries to address gastrointestinal infections and diarrhea. The botanical sources include goldenseal (Hydrastis canadensis), barberry (Berberis vulgaris), and Oregon grape (Mahonia aquifolium), all traditionally employed as digestive antimicrobials and bitter tonics.
Berberine is a natural component of many popular medicinal plants that ameliorates intestinal inflammation in humans through its modification of the gut microbiota. Its potential effect on the gut may provide a therapeutic target for SIBO. There is already evidence that the structural and numerical changes in the gut microbiota under pathological conditions can be reversed by berberine, which mediates modulatory effects on microglial activation and visceral hypersensitivity, and ameliorates intestinal inflammation in humans through antibacterial action.
The most rigorously designed study evaluating berberine specifically for SIBO is the BRIEF-SIBO trial. This investigator-initiated, single-center, open-label, double-arm randomized controlled trial recruited 180 patients allocated to an intervention group (berberine) and a control group (rifaximin). Each participant received 400 mg of the respective drug twice daily (800 mg daily) for 2 weeks, with a total follow-up period of 6 weeks. The primary outcome was a negative breath test; secondary outcomes included abdominal symptom relief and alteration in gut microbiota. Results of this trial are pending full publication. Evidence for berberine in SIBO specifically is therefore currently preliminary, and most existing data come from studies of IBS or broader gut dysbiosis.
Oregano has a long history of use in Mediterranean folk medicine for digestive complaints, including as an aid for indigestion, bloating, and intestinal infections. It was traditionally prepared as an infusion or, in more concentrated form, as an essential oil distillate, and was used in Greek, Italian, and Middle Eastern traditional healing systems.
Berberine, found in plants like goldenseal and Oregon grape, has been shown to inhibit bacterial adhesion and invasion. Oregano oil contains carvacrol and thymol, which can disrupt bacterial cell membranes. The most clinically relevant study examining herbal antimicrobials for SIBO — including oregano oil as a component — is the 2014 Johns Hopkins retrospective study. This study, published in Global Advances in Health and Medicine, compared herbal antimicrobial protocols to rifaximin in 104 patients with lactulose breath test-confirmed SIBO. The herbal protocol achieved a 46% response rate compared to 34% for rifaximin. Among patients who had already failed rifaximin, 57% responded to a subsequent course of herbal antimicrobials. The herbal formulas used in the study included commercially available products containing a combination of berberine, oregano, wormwood, lemon balm, and other botanical extracts. This study has limitations: it was retrospective, not a randomized controlled trial, and the sample size was modest.
A 2024 randomized clinical trial specifically examined combined herbal supplementation. A total of 179 SIBO-diagnosed patients underwent clinical evaluation and breath testing. Patients were categorized into hydrogen (H2-SIBO) and methane (CH4-SIBO) groups. The control group received standard antibiotic therapy and a low-FODMAP diet, while the intervention group received additional herbal antibiotics, probiotics, and prebiotics. After treatment, both groups exhibited reduced gas levels, particularly in CH4-SIBO. Clinical remission rates were higher in the intervention group, especially in CH4-SIBO cases.
Garlic has been used across virtually all ancient medical traditions — Egyptian, Greek, Ayurvedic, and Traditional Chinese Medicine — as an antimicrobial agent for intestinal parasites, infections, and digestive ailments. Allicin, the compound formed when garlic is crushed or chopped, is the primary bioactive component responsible for its antimicrobial properties. Traditional preparations ranged from raw garlic consumption to decoctions used specifically for intestinal worms and infections.
Allicin in garlic has broad-spectrum antimicrobial properties. These natural compounds often work through multiple mechanisms, potentially making it harder for bacteria to develop resistance compared to single-target pharmaceutical antibiotics. In the context of SIBO subtypes, allicin-containing formulations are most frequently discussed for methane-dominant SIBO (intestinal methanogen overgrowth), given activity against archaeal methanogens. Evidence is largely drawn from practitioner reports and the Johns Hopkins retrospective study cited above, in which allicin-based formulas were among the botanical agents used. Direct head-to-head randomized controlled trials isolating allicin for SIBO specifically have not been published in the peer-reviewed literature to date; evidence remains preliminary.
Neem has been a foundational herb in Ayurvedic medicine for more than two millennia, used for a broad range of conditions including intestinal parasites, skin disorders, fever, and infections. The bark, leaves, and seed oil were each employed in different preparations. In the context of digestive health, neem was considered a potent bitter agent and antiparasitic.
Neem appears in several practitioner-led botanical SIBO protocols and was included in the herbal formulas evaluated in the 2014 Johns Hopkins study. A ground-breaking study from Johns Hopkins in 2014 showed that herbal therapies are at least as effective as rifaximin (46% vs. 34%, respectively; P=0.24) for resolution of SIBO by lactulose breath test, and appear to be as effective as triple antibiotic rescue therapy for rifaximin nonresponders (57.1% vs. 60%, P=0.89), with fewer adverse effects. Experts in the field have used peppermint oil, neem, allicin, berberine (goldenseal or Oregon grape), wormwood (Artemisia), and oregano (Origanum). No placebo-controlled randomized controlled trials isolating neem specifically for SIBO have been identified in the peer-reviewed literature; evidence is preliminary and largely embedded within multi-herb study designs.
Peppermint has been used in European, Middle Eastern, and Asian herbal traditions for hundreds of years as a carminative and digestive antispasmodic. Prepared as infusions or essential oil preparations, it was applied for bloating, gas, abdominal cramps, and nausea. The European Pharmacopoeia includes peppermint leaf and peppermint oil as official monograph entries.
A number of double-blind, placebo-controlled studies have shown enteric-coated peppermint oil (standard dose 0.2 mL, 3 times a day) useful in improving the symptoms of IBS, and a 2002 case report of enteric-coated peppermint oil for SIBO described both laboratory and symptom improvements. Peppermint oil appears in the broader herbal SIBO protocol literature, most prominently in the Johns Hopkins study. Evidence for peppermint as a symptomatic agent in IBS (often overlapping with SIBO) is more robust than evidence for its direct role in SIBO eradication; the IBS evidence base includes multiple double-blind, placebo-controlled trials.
Ginger is one of the most extensively used medicinal plants across Ayurvedic, Traditional Chinese Medicine, and Unani traditions. Traditionally employed for nausea, indigestion, and poor gastric emptying, it has been a cornerstone digestive remedy for over 2,000 years. Preparations include fresh rhizome, dried powder, decoctions, and standardized extracts.
Ginger (Zingiber officinale) has a long history of traditional use as a gastroprotective agent and is supported by clinical and non-clinical data for improving gastric motility and related symptoms. Non-pharmaceutical approaches such as ginger extract can support motility. Due to this patient's history of recurrent intestinal methanogen overgrowth (IMO), the prevention protocol included diet, lifestyle, a combination of prokinetics, a probiotic, and a continuation of digestive enzymes. In the context of SIBO, ginger is studied primarily as a natural prokinetic agent rather than as a direct antimicrobial. Evidence directly linking ginger supplementation to SIBO eradication in randomized controlled trials is lacking; available data are primarily indirect (gastric motility studies in healthy subjects) or case report level.
Fermented foods — including yogurt, kefir, sauerkraut, and fermented dairy — have been consumed across numerous cultures as part of a traditional diet. The explicit application of live microbial preparations for intestinal bacterial disturbances became a focus of modern science in the 20th century, drawing on Élie Metchnikoff's early 1900s hypothesis that gut flora influenced health and longevity.
A 2017 meta-analysis and systematic review assessed probiotic efficacy for SIBO. Patients on probiotic usage showed an insignificant trend toward low SIBO incidence (RR=0.54; 95% CI, 0.19–1.52; P=0.24). The probiotics group showed a significantly higher SIBO decontamination rate than the nonprobiotic group (RR=1.61; 95% CI, 1.19–2.17; P<0.05). Also, the H2 concentration was significantly reduced among probiotic users (WMD=−36.35 ppm; 95% CI, −44.23 to −28.47 ppm; P<0.05). Although probiotics produced a marked decrease in abdominal pain scores, they did not significantly reduce daily stool frequency.
A 2025 network meta-analysis across randomized controlled trials found that probiotics (RR, 3.35; 95% CI: 2.29–4.89) showed statistically significant improvements in SIBO eradication rates compared to placebo. Notably, evidence remains heterogeneous due to differences in studied probiotic strains, dosing protocols, and SIBO subtypes. One trial demonstrated that Lactobacillus probiotics administered for 4 weeks resulted in symptom relief and a decrease in hydrogen breath gas levels in SIBO patients. Overall, the evidence for probiotics is considered promising but not yet definitive, with high variability across strain types and study designs.
A low-FODMAP diet eliminates several types of carbohydrates (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) that can promote too much bacterial growth in the gut. A 2021 systematic review and meta-analysis of randomized controlled trials found that a low-FODMAP diet was associated with the improvement of global symptoms (RR = 1.54; 95% CI 1.18 to 2), improvement of stool consistency, and a reduction trend in stool frequency compared with control interventions. This evidence base, however, focuses primarily on IBS patients rather than SIBO specifically.
Current evidence for the low FODMAP diet is weak: most reported studies are small and lack double or even single blinding, and a majority of the studies have focused on FODMAP eliminations rather than provocations. Trials eliminating FODMAPs from the diet have consistently been shown to reduce IBS symptoms.
The Low-FODMAP diet has the strongest research support for symptom relief, though most studies focused on IBS rather than SIBO specifically.
The elemental diet consists of pre-digested macronutrients (amino acids rather than intact proteins, simple sugars or oligosaccharides rather than complex carbohydrates, and minimal fat as medium-chain triglycerides) that are absorbed in the proximal small intestine, leaving minimal substrate for bacterial fermentation. The most widely referenced study in support of the elemental diet for SIBO is a 2004 study that involved 93 people with IBS and positive SIBO lactulose breath tests. After adhering to the elemental diet for 14 days, 80% of patients had a normal lactulose breath test. Those who still had abnormal results continued the diet for an additional week. At the end of the 21-day trial, 85% of participants had normal breath test results, indicating eradication of SIBO. This study is widely cited but was not a randomized controlled trial and lacked a control group. The elemental diet is the only plan studied directly as a SIBO treatment, with an 80–84% success rate, but it is challenging for many people and expensive.
Because the MMC occurs during fasting and is interrupted by feeding, frequent eating can reduce time spent in the interdigestive "cleaning wave" state. Understanding the "housekeeper" role of the migrating motor complex makes it easier to understand why dysfunction of the MMC might lead to SIBO. When the gut is not moving as it is supposed to, food particles that should be cleared out by the MMC remain in the small bowel. Some practitioners discuss meal spacing as a strategy to support MMC function, though direct clinical evidence in SIBO populations for this lifestyle modification specifically is sparse.
Dietary strategies, such as low-FODMAP and low-carbohydrate diets, may help reduce symptoms, especially in patients with complications like D-lactic acidosis. Lifestyle and supportive measures for SIBO include eating smaller, more frequent meals, staying upright after eating to encourage motility, and adequate hydration. These recommendations are based on mechanistic reasoning and clinical experience rather than high-quality controlled trials specifically in SIBO.
Altered bowel motility, visceral hypersensitivity, abnormal brain-gut interactions, and autonomic dysfunction are risk factors for SIBO. Phase III of the MMC with an antral origin can be induced in humans through intravenous administration of motilin, erythromycin, or ghrelin, whereas administration of serotonin or somatostatin induces phase III activity with duodenal origin. The role of the vagus nerve in control of the MMC seems to be restricted to the stomach. Chronic stress has been discussed as a modulator of gut motility and immune defenses through the autonomic nervous system, though the evidence for stress as a direct and independent cause of SIBO in humans is currently limited to mechanistic and associative data.
By improving gut motility, prokinetics help reduce the risk of relapse, which is one of the most common challenges for people with SIBO. The absence of the MMC has been associated with gastroparesis, intestinal pseudo-obstruction, and small intestinal bacterial overgrowth. Pharmaceutical prokinetics are a recognized approach in clinical settings. Regarding natural agents, non-pharmaceutical approaches such as ginger extract can support motility, and prevention protocols have included diet, lifestyle, a combination of prokinetics, a probiotic, and a continuation of digestive enzymes.
Allicin, the active sulfur compound from garlic, is particularly effective against methane-producing microbes associated with methane-dominant SIBO (intestinal methanogen overgrowth). The 2014 Chedid et al. study included allicin-based herbal protocols that outperformed rifaximin for SIBO breath-test normalization. Stabilized allicin supplements deliver the compound directly to the small intestine, targeting gram-negative bacterial species such as E. coli, Klebsiella, and Citrobacter implicated in hydrogen-dominant SIBO.
Bacillus clausii was specifically studied for SIBO treatment in a published clinical trial (Gabrielli et al., 2009, American Journal of Gastroenterology), showing comparable hydrogen breath-test normalization rates to antibiotic therapy. It is listed in the 2017 Zhong meta-analysis as among probiotic strains demonstrating SIBO decontamination efficacy.
Bacillus coagulans is a spore-forming probiotic listed in clinical SIBO treatment guidelines due to its ability to survive stomach acid and reach the small intestine intact. A 2023 meta-analysis of RCTs found B. coagulans improved IBS symptoms—including abdominal pain and bloating—that commonly overlap with SIBO. It is included in Optimal DX SIBO clinical protocols.
Berberine, a plant alkaloid from Berberis, Coptis, and related genera, has been studied head-to-head against rifaximin for SIBO. A 2014 study (Global Advances in Health and Medicine) found herbal protocols containing berberine achieved 46% breath-test normalization versus 34% with rifaximin. A PMC-published RCT protocol (BRIEF-SIBO study) directly evaluated berberine as a single agent against rifaximin in SIBO patients, documenting its modulation of gut microbiota composition and reduction of pathogenic bacteria.
Bifidobacterium species are included in SIBO probiotic protocols and the 2017 Zhong meta-analysis (18 studies, J Clin Gastroenterol). This meta-analysis found probiotic regimens containing Bifidobacterium strains effectively decontaminated the small intestine in 53.2–62.8% of cases and significantly reduced abdominal pain and hydrogen gas concentrations in SIBO patients.
Bifidobacterium longum was specifically used as post-antibiotic SIBO treatment support in a clinical study protocol (Redondo-Cuevas), and is included in the SIBO probiotic evidence reviewed by the 2017 Zhong meta-analysis. It reduces intestinal permeability and supports microbiome rebalancing after SIBO eradication.
In SIBO, excess bacteria in the small intestine deconjugate bile salts before they can form micelles, directly impairing fat digestion and causing fat malabsorption and diarrhea. The Mayo Clinic and clinical literature identify bile salt deconjugation as a primary mechanism of fat malabsorption and diarrhea in SIBO. Deconjugated bile salts are less efficiently reabsorbed and more cytotoxic, potentially injuring intestinal epithelium.
Carvacrol is the primary active antimicrobial compound of oregano oil and thyme oil, with well-documented biocidal activity against gram-positive and gram-negative bacteria implicated in SIBO. Multiple in vitro studies and the 2014 Chedid et al. clinical study (Global Advances in Health and Medicine) support carvacrol-containing preparations as effective as rifaximin for SIBO breath-test normalization.
SIBO is associated with reduced DAO levels due to bacterial damage to small intestinal villi, and simultaneously increases luminal histamine production, creating a reinforcing cycle of DAO deficiency and histamine intolerance. Serum DAO is lower in patients with SIBO than those without, as documented in clinical studies.
Garlic is used in SIBO treatment due to its allicin content, which is particularly effective against methane-producing archaea in methane-dominant SIBO. Herbal protocols incorporating garlic-derived allicin were shown in the 2014 Chedid et al. study to outperform rifaximin for SIBO breath-test normalization. Supplement-grade stabilized allicin extracts (not whole garlic) are preferred to avoid high-FODMAP fructans.
Ginger is used in SIBO management primarily as a natural prokinetic agent that enhances gastric motility and stimulates the migrating motor complex (MMC), reducing bacterial stasis and overgrowth recurrence. Clinical and pharmacological research confirms ginger's prokinetic properties, and clinical SIBO protocols recommend it (500–1,000 mg at night) to prevent relapse by maintaining gut motility after SIBO eradication.
SBI is clinically used as a medical food for managing chronic diarrhea in SIBO, per the published Wikipedia entry on EnteraGam and retrospective clinical series. Its IgG content binds bacterial antigens, potentially normalizing the microbial environment of the small intestine. Evidence is primarily clinical series and retrospective data rather than RCTs specific to SIBO.
Inulin, a prebiotic fiber, is identified in SIBO dietary literature as both a potentially beneficial and cautionary supplement. Authoritative sources (Nutrients 2022 narrative review cited by the Institute for Natural Medicine) include inulin as a soluble fiber supplement that may help manage SIBO symptoms, though high doses can worsen bloating by providing fermentable substrate for bacteria.
L-glutamine is used as supportive therapy in SIBO to repair intestinal barrier integrity compromised by bacterial overgrowth. Clinical SIBO protocols include L-glutamine (5 g twice daily) as a gut-lining repair agent post-antibiotic therapy. It is recognized by functional medicine practitioners and cited in published SIBO studies as supporting mucosal healing and reducing intestinal permeability.
Lactobacillus acidophilus has been studied in SIBO, with small studies showing comparable hydrogen breath-test normalization rates to antibiotic therapy. A 2017 meta-analysis (J Clin Gastroenterol, 18 studies) found that probiotics including L. acidophilus effectively decontaminated the small intestine in 53.2–62.8% of SIBO cases. Combined use with antibiotics increased decontamination rates to 85.8%.
Lactobacillus plantarum has demonstrated efficacy in SIBO-associated symptom reduction. Studies show L. plantarum 299v improved IBS symptoms linked to SIBO, and one study found L. plantarum outperformed antibiotics for functional abdominal bloating. The 2017 meta-analysis confirmed its role in small-intestinal decontamination and symptom improvement.
Lactobacillus rhamnosus (especially strain GG) has been included in SIBO probiotic protocols based on its well-documented effects on intestinal permeability and immune modulation. Clinical evidence places it among probiotic strains with evidence for managing SIBO-related gut dysbiosis and symptoms, including its recognition in systematic reviews and clinical protocol documents.
Peppermint oil demonstrates in vitro antibacterial activity against small intestinal bacteria, with activity against enteric pathogens relevant to SIBO. Laboratory evidence shows peppermint EO outperforms rifaximin (the antibiotic of choice for SIBO) in disc diffusion assays against E. coli. Clinical trials specifically for SIBO are absent, but mechanistic evidence is strong.
Monolaurin has in vitro activity against bacteria implicated in small intestinal bacterial overgrowth (including gram-positive organisms, H. pylori, and some gram-negatives). It is used in functional medicine SIBO protocols based on its broad antimicrobial spectrum and the premise that it spares beneficial bacteria. No human SIBO-specific clinical trials have been published.
N-Acetyl Cysteine (NAC) is used in SIBO treatment as a biofilm disruptor. NAC breaks disulfide bonds in bacterial biofilm matrices, exposing embedded bacteria to concurrent antimicrobials. Published clinical evidence (Cureus, PMC12701763) includes its use in herbal SIBO antimicrobial protocols, and Del Piano et al. found a regimen combining Lactobacillus strains with NAC significantly reduced small bowel bacterial overgrowth.
Oregano oil, standardized to carvacrol and thymol, is one of the most-studied herbal antimicrobials for SIBO. The 2014 Chedid et al. study included oregano-containing herbal protocols that achieved breath-test normalization comparable to or exceeding rifaximin. In vitro studies document carvacrol's biocidal activity against gram-positive and gram-negative bacteria found in the jejunum, ileum, and colon, and anti-biofilm properties relevant to treatment-resistant SIBO.
Peppermint oil is used in SIBO management as both a natural antimicrobial and prokinetic agent. Its active compound menthol relaxes smooth muscle and stimulates gut motility, while its antimicrobial properties help reduce bacterial load. Multiple functional medicine SIBO protocols and clinical reviews cite peppermint oil for SIBO symptom relief and relapse prevention.
Psyllium is a soluble fiber recommended to help manage SIBO symptoms and support gut regularity. A narrative review published in Nutrients (2022) cited by the Institute for Natural Medicine identified psyllium as a fiber supplement that can help curb SIBO symptoms by supporting gut motility and microbiome balance without significantly increasing fermentable substrate.
Saccharomyces boulardii is a probiotic yeast with multiple RCTs demonstrating efficacy for SIBO. A 2024 randomized placebo-controlled study in patients with decompensated cirrhosis found SIBO absent in 80% of the probiotic group vs. 23.1% of placebo (p=0.002) after 3 months. A 2017 meta-analysis (18 studies, J Clin Gastroenterol) found probiotics including S. boulardii significantly reduced bacterial overgrowth and hydrogen breath test concentrations.
Thyme contains thymol, a phenolic compound with broad-spectrum antibacterial activity complementary to carvacrol from oregano oil. Thymol is active against gram-positive and gram-negative bacteria relevant to SIBO and enhances carvacrol's antimicrobial effects. Thyme extract is included in herbal SIBO protocols (regenerated.health) and its compounds are documented in SIBO antimicrobial literature.
Barberry's broad-spectrum antimicrobial activity, including against common small intestinal bacterial overgrowth pathogens, provides mechanistic plausibility for SIBO support. This is a traditional and mechanistically-inferred use rather than one supported by clinical SIBO-specific trials.
Caprylic acid is used by integrative practitioners for small intestinal bacterial/fungal overgrowth based on its broad antimicrobial properties. Its selective activity against Candida and some bacteria, combined with rapid absorption via the portal vein before reaching the distal gut, makes the SIBO rationale less direct than for colonic overgrowth. No human RCT exists for this specific indication.
Goldenseal is used in integrative and herbal medicine for small intestinal bacterial overgrowth (SIBO), based on berberine's documented antimicrobial activity against enteric bacteria. This is an extension of its traditional anti-infective gastrointestinal use; no RCTs of goldenseal for SIBO have been published.
Go back